Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration

Human Gene Therapy

Volumn 23, Issue 9, 2012, Pages 932-942

  Sakkhachornphop, Supachai ^a   Barbas, Carlos F ^b   Keawvichit, Rassamee ^a   Wongworapat, Kanlaya ^a   Tayapiwatana, Chatchai ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; VIRUS GLYCOPROTEIN; ZINC FINGER PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL COMMUNICATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOLECULAR CLONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS REPLICATION;

CELL LINE; DNA-BINDING PROTEINS; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRUS INTEGRATION; ZINC FINGERS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 84866325679     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.124     Document Type: Article

References (63)

1. Agosto, L.M., Yu, J.J., Dai, J., et al. (2007). HIV-1 integrates into resting CD4+ T cells even at lowinoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368, 60-72. (Pubitemid 47599558)
2. Balakrishnan, M., and Jonsson, C.B. (1997). Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. J. Virol. 71, 1025-1035. (Pubitemid 27030273)
3. Barbosa, P., Charneau, P., Dumey, N., et al. (1994). Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res. Hum. Retroviruses 10, 53-59.
4. Bohjanen, P.R., Colvin, R.A., Puttaraju, M., et al. (1996). A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res. 24, 3733-3738. (Pubitemid 26335382)
5. Bugreev, D.V., Baranova, S., Zakharova, O.D., et al. (2003). Dynamic, thermodynamic, and kinetic basis for recognition and transformation of DNA by human immunodeficiency virus type 1 integrase. Biochemistry 42, 9235-9247. (Pubitemid 36935434)
6. Bushman, F.D., and Craigie, R. (1991). Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U.S.A. 88, 1339-1343. (Pubitemid 21916220)
7. Cavert, W., Notermans, D.W., Staskus, K., et al. (1997). Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964. (Pubitemid 27209096)
8. Charpentier, C., Karmochkine, M., Laureillard, D., et al. (2008). Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 9, 765-770.
9. Chen, L.F., Hoy, J., and Lewin, S.R. (2007). Ten years of highly active antiretroviral therapy for HIV infection. Med. J. Aust. 186, 146-151. (Pubitemid 46331200)
10. Cohli, H., Fan, B., Joshi, R.L., et al. (1994). Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). Antisense Res. Dev. 4, 19-26. (Pubitemid 24267002)
11. De Clercq, E. (2001). New developments in anti-HIV chemotherapy. Curr. Med. Chem. 8, 1543-1572. (Pubitemid 33076802)
12. Delelis, O., Malet, I., Na, L., et al. (2009). The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37, 1193-1201.
13. Deprez, E., Barbe, S., Kolaski, M., et al. (2004). Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 65, 85-98. (Pubitemid 38113889)
14. Donehower, L.A., and Varmus, H.E. (1984). A mutant murine leukemia virus with a single missense codon in pol is defective in a function affecting integration. Proc. Natl. Acad. Sci. U.S.A. 81, 6461-6465. (Pubitemid 15221854)
15. Dreier, B., Beerli, R.R., Segal, D.J., et al. (2001). Development of zinc finger domains for recognition of the 5¢-ANN-3¢ family of DNA sequences and their use in the construction of artificial transcription factors. J. Biol. Chem. 276, 29466-29478.
16. Dull, T., Zufferey, R., Kelly, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471. (Pubitemid 28471781)
17. Evering, T.H., and Markowitz, M. (2008). Raltegravir: An integrase inhibitor for HIV-1. Expert Opin. Investig. Drugs 17, 413-422. (Pubitemid 351578192)
18. Flexner, C. (2007). HIV drug development: The next 25 years. Nat. Rev. Drug Discov. 6, 959-966. (Pubitemid 350201786)
19. Grant, P., and Zolopa, A. (2008). Integrase inhibitors: A clinical review of raltegravir and elvitegravir. J. HIV Ther. 13, 36-39.
20. Gupta, R.K., and Pillay, D. (2007). HIV resistance and the developing world. Int. J. Antimicrob. Agents 29, 510-517. (Pubitemid 46562507)
21. Han, Y., Lassen, K., Monie, D., et al. (2004). Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78, 6122-6133. (Pubitemid 38715910)
22. Hicks, C., Gulick, R.M., Roquebert, B., et al. (2009). Raltegravir: The first HIV type 1 integrase inhibitor: Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. Clin. Infect. Dis. 48, 931-939.
23. Jurriaans, S., de Ronde, A., Dekker, J., et al. (1992). Analysis of human immunodeficiency virus type 1 LTR-LTR junctions in peripheral blood mononuclear cells of infected individuals. J. Gen. Virol. 73, 1537-1541.
24. Katz, R.A., and Skalka, A.M. (1994). The retroviral enzymes. Annu. Rev. Biochem. 63, 133-173. (Pubitemid 24218631)
25. Katzman, M., and Sudol, M. (1996). Influence of subterminal viral DNA nucleotides on differential susceptibility to cleavage by human immunodeficiency virus type 1 and visna virus integrases. J. Virol. 70, 9069-9073. (Pubitemid 26378501)
26. Kim, S.Y., Byrn, R., Groopman, J., et al. (1989). Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression. J. Virol. 63, 3708-3713. (Pubitemid 19205441)
27. LaFemina, R.L., Callahan, P.L., and Cordingley, M.G. (1991). Substrate specificity of recombinant human immunodeficiency virus integrase protein. J. Virol. 65, 5624-5630.
28. Lee, N.S., Dohjima, T., Bauer, G., et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500-505. (Pubitemid 34495938)
29. Levy, J.A. (2007). Step involved in HIV:cell interaction and virus entry. In HIV and the Pathogenesis of AIDS. (ASM Press, Washington, D.C.), p. 77.
30. Levy-Mintz, P., Duan, L., Zhang, H., et al. (1996). Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J. Virol. 70, 8821-8832. (Pubitemid 26378466)
31. Li, Z., Dullmann, J., Schiedlmeier, B., et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296, 497. (Pubitemid 34408663)
32. Liem, S.E., Ramezani, A., Li, X., et al. (1993). The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum. Gene Ther. 4, 625-634. (Pubitemid 24305759)
33. Liszewski, M.K., Yu, J.J., and O'Doherty, U. (2009). Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 47, 254-260.
34. Lu, X., Yu, Q., Binder, G.K., et al. (2004). Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 78, 7079-7088. (Pubitemid 38781546)
35. Marasco, W.A., Haseltine, W.A., and Chen, S.Y. (1993). Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. U.S.A. 90, 7889-7893. (Pubitemid 23250056)
36. Marchetti, A., Buttitta, F., Miyazaki, S., et al. (1995). Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. J. Virol. 69, 1932-1938.
37. Mbisa, J.L., Martin, S.A., and Cane, P.A. (2011). Patterns of resistance development with integrase inhibitors in HIV. Infect. Drug Resist. 4, 65-76.
38. O'Doherty, U., Swiggard, W.J., Jeyakumar, D., et al. (2002). A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J. Virol. 76, 10942-10950. (Pubitemid 35176211)
39. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., et al.; HIV Outpatient Study Investigators. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860. (Pubitemid 28135961)
40. Pauza, C.D. (1990). Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination. Virology 179, 886-889.
41. Pauza, C. D., Trivedi, P., McKechnie, T. S., et al. (1994). 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 205, 470-478. (Pubitemid 24371688)
42. Ramezani, A., Ma, X.Z., Nazari, R., et al. (2002). Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front. Biosci. 7, a29-a36.
43. Reisman, D., and Sugden, B. (1986). Trans-activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol. Cell. Biol. 6, 3838-3846.
44. Reynolds, L., Ullman, C., Moore, M., et al. (2003). Repression of the HIV-1 5¢ LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc. Natl. Acad. Sci. U.S.A. 100, 1615-1620. (Pubitemid 36254496)
45. Sakkhachornphop, S., Jiranusornkul, S., Kodchakorn, K., et al. (2009). Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions. Protein Sci. 18, 2219-2230.
46. Schrager, L.K., and D'Souza, M.P. (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280, 67-71. (Pubitemid 28414999)
47. Segal, D.J., Goncalves, J., Eberhardy, S., et al. (2004). Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J. Biol. Chem. 279, 14509-14519. (Pubitemid 38618838)
48. Shaheen, F., Duan, L., Zhu, M., et al. (1996). Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 70, 3392-3400. (Pubitemid 26157321)
49. Sherman, P.A., and Fyfe, J.A. (1990). Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl. Acad. Sci. U.S.A. 87, 5119-5123.
50. Staunstrup, N. H., Moldt, B., Mates, L., et al. (2009). Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol. Ther. 17, 1205-1214.
51. Su, K., Wang, D., Ye, J., et al. (2009). Site-specific integration of retroviral DNA in human cells using fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc-finger protein E2C. Methods 47, 269-276.
52. Tamhane, M., and Akkina, R. (2008). Stable gene transfer of CCR5 and CXCR4 siRNAs by Sleeping Beauty transposon system to confer HIV-1 resistance. AIDS Res. Ther. 5, 16.
53. Tan, W., Zhu, K., Segal, D.J., et al. (2004). Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J. Virol. 78, 1301-1313. (Pubitemid 38095840)
54. Tesio, M., Gammaitoni, L., Gunetti, M., et al. (2008). Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors. Stem Cells 26, 1620-1627.
55. Tewari, D., Notkins, A.L., and Zhou, P. (2003). Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. J. Gene Med. 5, 182-189. (Pubitemid 40310372)
56. van den Ent, F.M., Vink, C., and Plasterk, R.H. (1994). DNA substrate requirements for different activities of the human immunodeficiency virus type 1 integrase protein. J. Virol. 68, 7825-7832. (Pubitemid 24362669)
57. Vercruysse, T., Pardon, E., Vanstreels, E., et al. (2010). An intrabody based on a llama single-domain antibody targeting the N-terminal a-helical multimerization domain of HIV-1 Rev prevents viral production. J. Biol. Chem. 285, 21768-21780.
58. Vink, C., and Plasterk, R.H. (1993). The human immunodeficiency virus integrase protein. Trends Genet. 9, 433-438.
59. Vink, C., van Gent, D. C., Elgersma, Y., et al. (1991). Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. J. Virol. 65, 4636-4644.
60. Whitcomb, J.M., Kumar, R., and Hughes, S.H. (1990). Sequence of the circle junction of human immunodeficiency virus type 1: Implications for reverse transcription and integration. J. Virol. 64, 4903-4906. (Pubitemid 20329811)
61. Yates, J.L., Warren, N., and Sugden, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815. (Pubitemid 15130835)
62. Yoshinaga, T., and Fujiwara, T. (1995). Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. J. Virol. 69, 3233-3236.
63. Zufferey, R., Dull, T., Mandel, R.J., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880. (Pubitemid 28520853)